Expansion of the CELLFLOAT System Using Rotary Suspension Culture Technology

「For CELLFLOAT®-related equipment, in addition to the track record established in Japan, the Company will pursue overseas expansion going forward to generate orders.」

「During the six-month interim consolidated accounting period, the life sciences business recorded sales related to the CellFloat three-dimensional rotating suspension culture system, as well as sales of equipment maintenance services and consumables.」

「During the six-month interim consolidated accounting period, sales in the life sciences and equipment development businesses remained at the same level as the previous year. In the life sciences business, sales of the automated cell culture system MakCell®, together with equipment maintenance and consumables sales, contributed to revenue.」

「Tokyo Medical and Dental University also successfully generated human intestinal organoids (HIOs) derived from iPS cells using the Company's proprietary three-dimensional rotating suspension culture system.」

「Toward the fiscal year-end, the Company is promoting order-taking and sales activities for general-purpose automated cell culture systems and other culture equipment in the life sciences business, centered on next-generation processing and polishing equipment identified as a priority new business field in the equipment development business.」

「Sales in this business are also expected to be weighted toward the second half of the fiscal year. Toward the second half, the Company plans to sell large-scale automated cell culture systems in the life sciences business and next-generation processing and polishing equipment, the priority field of the equipment development business, including PAP, CARE and PCVM.」

「Going forward, the Company will pursue overseas expansion of CellPet 3D-iPS® and CellPet® CUBE to generate orders.」

「During the second quarter, sales of the large-scale automated cell culture system KB-4000, MakCell and prototypes of drug-release device manufacturing equipment under development drove performance. The large-scale automated culture equipment is being sold to pharmaceutical companies and other customers, and the Company will continue to focus on this business while promoting sales of general-purpose equipment using the CELLFLOAT® system.」

「Over the medium to long term, the Company will promote sales of general-purpose equipment using the CELLFLOAT® system, while focusing on the equipment development business and cultivating new business fields within that business.」

「During the third quarter, sales of general-purpose automated culture equipment other than the CELLFLOAT® system, including CellPet II and its successor model MakCell, drove performance.」

「During the second quarter, sales of general-purpose automated culture equipment other than the CELLFLOAT® system, including CellPet II and its successor model MakCell, drove performance. In particular, the Company began full-scale sales of the new MakCell product and plans to expand sales from the third quarter onward.」

「As a short-term strategy, the Company has worked to shift its sales mix from general-purpose equipment using the CELLFLOAT® system, namely CellPet 3D-iPS® and CellPetr FT®, to equipment development projects. This has progressed steadily, beginning with the development of a quartz-crystal wafer processing system.」

「The shift in the sales mix from general-purpose equipment using the CELLFLOAT® system, namely CellPet 3D-iPS and CellPet FT, to equipment development projects has also progressed steadily.」

「The shift in the sales mix from general-purpose equipment using the CELLFLOAT® system, namely CellPet 3D-iPS and CellPet FT, to equipment development projects has also progressed steadily.」

「During the fiscal year, the Company completed an automated system for large-scale passaging culture of iPS cells. In the following fiscal year, it plans to install the system at the Faculty of Medicine, Osaka University, and conduct field testing.」

「During the fiscal year, the Company also worked to shift its sales mix from general-purpose equipment using the CELLFLOAT® system, namely CellPet 3D-iPS and CellPet FT, to contract-manufactured products in the equipment development business.」

「During the fiscal year, the Company also worked to shift its sales mix from general-purpose equipment using the CELLFLOAT® system, namely CellPet 3D-iPS and CellPet FT, to contract-manufactured products in the equipment development business.」

「During the fiscal year, the Company worked to shift its sales mix from general-purpose equipment using the CELLFLOAT® system, namely CellPet 3D-iPS and CellPet FT, to contract-manufactured products in the equipment development business.」

「As part of further research into this large-scale cell culture technology, the business also promoted the development of a large-scale spheroid culture technology specialized for iPS cells and successfully commercialized CellPet 3D-iPS and CellPet FT.」

「Sales of the CELLFLOAT system, which uses the Company's proprietary rotating suspension culture technology, including CellPet 3D-iPS and CellPet FT, as well as sales related to gravure printing testing machines and quartz-crystal wafer processing equipment in the equipment development business, contributed to performance. The Company also pursued research and development actively. As a result, revenue was ¥82.419 million and the segment loss was ¥72.236 million.」